Ablaze Pharmaceuticals Snags $75M
San Diego- and Shanghai-based Ablaze Pharmaceuticals which is developing cancer treatments, said this morning that it has raised $75M in its Series A funding round. The funding was co-led by Vivo Capital and AdvanTech Capital, and also included RAYZ Investments, Nan Fung Life Sciences, Pivotal bioVenture Partners China, venBio Partners, Samsara BioCapital and Venrock Healthcare Capital Partners. Ablaze Pharmaceuticals is led by co-founder and President and CEO Dr. Alex Qiao. Ablaze has a partnership with San Diego based RayzeBio, and is focused on the Greater China market.